Literature DB >> 25441934

Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.

S Nicholson1, A Hanby1, K Clements1, O Kearins1, G Lawrence1, D Dodwell1, H Bishop1, A Thompson2.   

Abstract

The diagnosis and surgical management of screen-detected Ductal Carcinoma In Situ (DCIS) remains controversial including a range of axillary approaches and consequent morbidity. This study examined the management of the axilla in all patients with DCIS presenting through the United Kingdom National Health Service Breast Screening Programme (UK NHS BSP). Retrospective analysis of the UK NHS BSP identified 26,696 women initially diagnosed with DCIS over the 8 years 1 April 2003-31 March 2011. The final breast pathology of these women was upgraded to invasive ductal cancer in 5564 (20.8%) women or micro-invasive cancer in 1031 (3.9%) women. At first operation, 5290 (26.3%) of the 20,094 women who had a final post-operative diagnosis of DCIS only underwent axillary surgery (72.4% at the time of mastectomy, 23.8% breast conservation surgery, 3.8% axillary surgery alone). Performance of axillary surgery reflected increasing tumour size, micro-invasion or increasing nuclear grade for the final diagnosis of DCIS. More extensive nodal surgery was performed in those undergoing mastectomy; 10.8% of women had more than 8 nodes removed. Overall, 12.0% of women with invasive cancer, 1.7% with micro-invasion, and 0.2% with DCIS alone, were ultimately node positive. Improved pre-operative sampling of DCIS, axillary assessment by ultrasound with needle biopsy for suspected metastases, risk stratification for sentinel node biopsy (for high grade or extensive DCIS) and avoiding axillary clearance for a pre-operative diagnosis of DCIS alone should reduce unnecessary axillary surgery. Standards using such criteria for axillary surgery in screen-detected DCIS should be integrated into the NHS BSP. Crown
Copyright © 2014. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Axillary surgery; Breast screening; DCIS; Extent of surgery

Mesh:

Year:  2014        PMID: 25441934     DOI: 10.1016/j.ejso.2014.09.003

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  11 in total

1.  Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?

Authors:  Melissa Pilewskie; Maria Karsten; Julia Radosa; Anne Eaton; Tari A King
Journal:  Ann Surg Oncol       Date:  2016-03-09       Impact factor: 5.344

2.  Prediction of Sentinel Lymph Node Metastasis in Breast Ductal Carcinoma In Situ Diagnosed by Preoperative Core Needle Biopsy.

Authors:  Kai Zhang; Lang Qian; Qian Zhu; Cai Chang
Journal:  Front Oncol       Date:  2020-11-10       Impact factor: 6.244

3.  Surgeons' preferences for using sentinel lymph node biopsy in patients with ductal carcinoma in situ.

Authors:  Claudia J C Meurs; Janine A van Til; Marian B E Menke-Pluijmers; Stefanie de Vet; Sabine Siesling; Pieter J Westenend
Journal:  PLoS One       Date:  2022-06-06       Impact factor: 3.752

4.  The Role of Sentinel Lymph Node Biopsy in Patients With B5c Breast Cancer Diagnosis.

Authors:  Piero Fregatti; Marco Gipponi; Raquel Diaz; Raffaele DE Rosa; Federica Murelli; Francesca Depaoli; Francesca Pitto; Ilaria Baldelli; Gabriele Zoppoli; Marcello Ceppi; Daniele Friedman
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

5.  Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy.

Authors:  Nai-Si Huang; Jing Si; Ben-Long Yang; Chen-Lian Quan; Jia-Jian Chen; Jiong Wu
Journal:  Cancer Med       Date:  2017-12-22       Impact factor: 4.452

6.  DCIS and axillary nodal evaluation: compliance with national guidelines.

Authors:  Katrina B Mitchell; Heather Lin; Yu Shen; Alfred Colfry; Henry Kuerer; Simona F Shaitelman; Gildy V Babiera; Isabelle Bedrosian
Journal:  BMC Surg       Date:  2017-02-07       Impact factor: 2.102

7.  Clinical practice guidelines for ductal carcinoma in situ: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.

Authors:  Ang Zheng; Zi-Ning Jin; Meng-Yao Cui; Bo Chen; Fan Yao; Feng Jin; Ying-Ying Xu
Journal:  Chin Med J (Engl)       Date:  2021-06-10       Impact factor: 2.628

8.  National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons.

Authors:  Ryerson Seguin; Lashan Peiris
Journal:  Curr Oncol       Date:  2021-03-29       Impact factor: 3.677

9.  De-escalating axillary surgery in early-stage breast cancer.

Authors:  Eliza H Hersh; Tari A King
Journal:  Breast       Date:  2021-12-15       Impact factor: 4.254

10.  Controversial Areas in Axillary Staging: Are We Following the Guidelines?

Authors:  Ava Armani; Sasha Douglas; Swati Kulkarni; Anne Wallace; Sarah Blair
Journal:  Ann Surg Oncol       Date:  2021-07-24       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.